Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dopamine receptor D2 regulates glioblastoma survival and death through MET and death receptor 4/5

25 Mar 2023

Abstract excerpt

Recent studies indicate that signaling molecules traditionally associated with central nervous system function play critical roles in cancer. Dopamine receptor signaling is implicated in various cancers including glioblastoma (GBM) and it is a recognized therapeutic target, as evidenced by recent clinical trials with a selective dopamine receptor D2 (DRD2) inhibitor ONC201. Understanding the molecular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Stress, Anesthesia, and Immune Response
Share to Glioma Diagnosis and Treatment
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36972629
DOI: 10.1016/j.neo.2023.100894

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dopamine receptor D2 regulates glioblastoma survival and death through MET and death receptor 4/5PMID 36972629Read ↗

Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastomaSemantic proximity Read ↗

Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitorsSemantic proximity Read ↗

Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 AntagonismSemantic proximity Read ↗

Activation of dopamine receptor 2 (DRD2) prompts transcriptomic and metabolic plasticity in glioblastomaSemantic proximity Read ↗

The Dopamine D2 Receptor Contributes to the Spheroid Formation Behavior of U87 Glioblastoma Cells.Semantic proximity Read ↗

Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cellsSemantic proximity Read ↗

Mitochondrial enzyme GLUD2 plays a critical role in glioblastoma progressionSemantic proximity Read ↗

DRD1 suppresses cell proliferation and reduces EGFR activation and PD‐L1 expression in NSCLCSemantic proximity Read ↗

BCL2L13 promotes mitophagy through DNM1L-mediated mitochondrial fission in glioblastomaSemantic proximity Read ↗

Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.Semantic proximity Read ↗

p53 and miR‐210 regulated NeuroD2, a neuronal basic helix–loop–helix transcription factor, is downregulated in glioblastoma patients and functions as a tumor suppressor under hypoxic microenvironmentSemantic proximity Read ↗

Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.